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We thank Dr Wadei and Dr Haley for their invaluable
comments.1 A detailed response to each point is given below.
1. Assuming that the rats actually drank all the thiazide-
loaded water and accordingly received 1.5–1.75 mg thia-
zide/day, how does this dose translate to clinical practice or
to the dose used in the ALLHAT or AASK trials?
We agree that the dose of diuretics is an important issue in
this study. Rats are known to be resistant to thiazides, and
experimental studies typically use doses between 3 and 80 mg/
kg/day of hydrochlorothiazide (HCTZ). We desired to use the
minimum dose that causes mild potassium depletion
comparable to the effect of moderate low potassium diet. To
achieve this, we performed pilot studies and determined that
10 mg/kg/day was the lowest dose that caused mild hypoka-
lemia. Furthermore, with this dose, the changes in blood
pressure, sodium and potassium excretion, serum bicarbo-
nate, potassium, and metabolic changes are similar to those
observed in subjects receiving thiazides, even at a low dose.2–4
Although high doses of diuretics have a higher
incidence of metabolic side-effects, recent studies have
documented that use of even low-dose thiazide further
increased the incidence of a new onset of diabetes.2 Other
studies have also shown that a significant number of the
side effects, such as diabetes, lower serum potassium,
hyperuricemia, and hyperlipidemia, are increased in
subjects despite using low doses of thiazides.5 Further-
more, most diuretics increase serum uric acid even at low
dose,3 including HCTZ 6.25–25 mg/day.6,7 Thus, we believe
that 10 mg/kg/day of HCTZ is an adequate dose to test our
hypothesis in an animal model.
2. What is the equivalent of 20 weeks of rat age in
human life?
Our rats were 6–7 weeks old when the study was started
and they were studied for 20 weeks. This period
corresponds to that of a young adult.8 Because the life
span of Sprague–Dawley rats is around 2–2.5 years, the
study time was one-fifth to one-sixth of the life span,
which translates to 10–15 years of human life.
3. Can the same findings be reproduced if another rat
species was used?
We have not performed the study in other rat species. In
previous studies, Komatsu K et al.9 demonstrated HCTZ-
induced glomerular ischemia associated with efferent arter-
iolar constriction in mature, spontaneously hypertensive rats.
Additionally, Ono Y et al.10 also documented that HCTZ
increased glomerular capillary pressure, glomerular injury
and proteinuria in mature, spontaneously hypertensive rats
with NG-nitro-L-arginine methyl ester administration.
4. Basic science research continues to be the best tool to
build breakthrough clinical research, but until studies
dedicated to examine the effect of chronic thiazide use on
histological findings and/or kidney function in humans
become available, I think extrapolating from animal
studies risks unwarranted changes in clinical practices
and public confusion.
We agree that it is important to determine if renal
injury occurs in humans similar to that observed in
rats with thiazide usage. However, there is ample evidence
that thiazide usage does not provide renal protection and
its use is often associated with renal progression.11
Although renal biopsy in individuals on thiazide might
be considered, the observation that it is associated
with mild renal injury makes renal biopsy ethically
challenging. Animal experimentation has provided key
insights into diverse areas from glomerulonephritis to
transplantation due to similarities in mammalian physio-
logy. Our observation that subtle renal injury occurs
in thiazide-treated rats suggests the need to further
investigate whether this potential untoward side effect
occurs in humans.
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